Cover Image
市場調查報告書

傷寒症:開發平台分析

Typhoid Fever - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 203746
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
傷寒症:開發平台分析 Typhoid Fever - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 47 Pages
簡介

傷寒症是造成腹瀉和皮疹的感染疾病。最常是由被稱為傷寒菌(S.typhi)的細菌引起。常見的症狀有腹部壓痛,興奮,發冷,譫妄症,幻覺,重度的疲勞·虛弱等。治療方法包含抗生素和支持療法。

本報告提供傷寒症的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

傷寒症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Chongqing Zhifei Biological Products Co., Ltd.
  • GlaxoSmithKline Plc
  • Prokarium Limited
  • Protein Potential, LLC
  • Shantha Biotechnics Limited
  • USV Limited
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (typhoid fever + shigellosis) multivalent vaccine
  • Typhella
  • Typhetec
  • typhoid + paratyphoid (bivalent) vaccine
  • typhoid + paratyphoid vaccine
  • typhoid + pneumococcal vaccine
  • typhoid and paratyphoid fever vaccine
  • polysaccharide vaccine
  • typhoid vaccine
  • ViCRM-197

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9546IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Pipeline Review, H2 2017, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.

Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 1, 6, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Typhoid Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Typhoid Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Typhoid Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Typhoid Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Typhoid Fever (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Typhoid Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Typhoid Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Typhoid Fever - Overview
    • Typhoid Fever - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Typhoid Fever - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Typhoid Fever - Companies Involved in Therapeutics Development
    • GlaxoSmithKline Plc
    • Indian Immunologicals Ltd
    • Nanotherapeutics Inc
    • Prokarium Ltd
    • Protein Potential LLC
    • Sanofi Pasteur SA
    • Shantha Biotechnics Pvt Ltd
    • SK Chemicals Co Ltd
    • Zydus Cadila Healthcare Ltd
  • Typhoid Fever - Drug Profiles
    • (paratyphoid (bivalent) + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (paratyphoid + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (paratyphoid + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (shigella + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Streptococcal pneumonia + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EUC-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Typhella - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ViCRM-197 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Typhoid Fever - Dormant Projects
  • Typhoid Fever - Discontinued Products
  • Typhoid Fever - Product Development Milestones
    • Featured News & Press Releases
      • Oct 08, 2012: Typhim Vi - Typhoid Polysaccharide Vaccine - antigen levels below required specification
      • Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine
      • Jun 23, 2011: Sanofi Pasteur's Typhim VI Receives Prequalification from World Health Organization
      • Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
      • Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine
      • Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine
      • Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study
      • Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Typhoid Fever, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Typhoid Fever - Pipeline by Indian Immunologicals Ltd, H2 2017
  • Typhoid Fever - Pipeline by Nanotherapeutics Inc, H2 2017
  • Typhoid Fever - Pipeline by Prokarium Ltd, H2 2017
  • Typhoid Fever - Pipeline by Protein Potential LLC, H2 2017
  • Typhoid Fever - Pipeline by Sanofi Pasteur SA, H2 2017
  • Typhoid Fever - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017
  • Typhoid Fever - Pipeline by SK Chemicals Co Ltd, H2 2017
  • Typhoid Fever - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017
  • Typhoid Fever - Dormant Projects, H2 2017
  • Typhoid Fever - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Typhoid Fever, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top